Navigation Links
CareFusion Reports Second Quarter Results
Date:2/9/2010

ations was $73 million, or $0.33 per diluted share.

Excluding nonrecurring items, adjusted operating income for the second quarter declined to $149 million from $177 million and adjusted net income decreased $22 million to $88 million, or $0.39 on an adjusted basis per diluted share.

Operating expenses, including selling, general and administrative (SG&A), research and development (R&D), and restructuring and acquisition integration charges in the second quarter totaled $351 million or 34 percent of total revenue. Excluding $22 million of nonrecurring items, adjusted operating expenses in the second quarter totaled $329 million, or 32 percent of total revenue. Adjusted SG&A expenses were $292 million, and R&D investments totaled $37 million.

Critical Care Technologies

Second quarter revenue for the Critical Care Technologies segment, which includes the company's Dispensing, Infusion and Respiratory businesses, increased 1 percent to $682 million, driven by a strong performance in the company's Respiratory business. On a constant currency basis, revenue decreased by 1 percent. Segment profit decreased to $111 million from $146 million. Adjusted segment profit decreased to $126 million from $148 million driven by the impact of the slowdown in hospital capital spending and higher allocated costs from standing up as a public company, which were only partially offset by strong results in the company's Respiratory busine
'/>"/>

SOURCE CareFusion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. CareFusion Announces Six New Pyxis(R) Technologies at the ASHP Midyear Clinical Meeting and Exhibition
2. CareFusion Earns Top Ranking in MD Buyline and KLAS Reports
3. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
4. CareFusion Shipping Ventilators to CDC for National Emergency Preparedness
5. CareFusion Moves First Quarter Earnings Announcement to November 5
6. CareFusion Announces 5-Year, Sole Source Pyxis(R) Perioperative Solutions Agreement With CHRISTUS Health
7. CareFusion Reports First Quarter Results, Raises Full-Year Outlook
8. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
9. CareFusion Signs Multi-Year Technology Licensing Agreement for Masimo Rainbow SET(R) Pulse CO-Oximetry(TM)
10. CareFusion Will Host an Earnings Conference Call on Feb. 9 to Discuss the Results for the Second Quarter of Fiscal 2010
11. FDA Lifts Injunction on Manufacture and Sale of CareFusion Alaris(R) SE Pump
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... et MADRID , June ... orale (extrait 10503) effectuée lors de la réunion ... PharmaMar communique que Janssen Research & ... de l,étude multicentrique de phase III SAR3007 qui ... progression (PFS) avec la trabectédine (YONDELIS ® ) ...
(Date:6/1/2015)... , June 2, 2015 Amgen ... with Roche on a Phase 1b study to ... Amgen,s investigational oncolytic immunotherapy, in combination with Roche,s ... in patients with triple-negative breast cancer and colorectal ... is an investigational oncolytic immunotherapy designed to selectively ...
(Date:6/1/2015)... June 1, 2015 Lee Tran ... the Snapchat and Yik Yak ... against one of the most promising biotechnology start-ups in ... Meyer and Jeffrey Sabados .  LTL represents ... a former colleague and fellow scientist at the Massachusetts ...
Breaking Medicine Technology:PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 2PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 3PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 4PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 5PharmaMar annonce que l'étude Janssen montre que la Trabectédine améliore la lutte contre la maladie chez les patients atteints du sarcome des tissus mous à un stade avancé 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 2Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 3Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 4Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 5Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 6Amgen Announces Collaboration With Roche On Cancer Immunotherapy Study With Investigational Medicines Talimogene Laherparepvec And Atezolizumab 7Lee Tran & Liang LLP Files Co-Founder Lawsuit against Leading Biotech Start-up Resilience 2
... , ... ... ... ...
... ... ... ... , ...
Cached Medicine Technology:Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 2Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 3Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 4Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 5Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 6Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 7Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 8Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 9Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 10Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 11Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 12Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 13Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 14Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 15Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 16Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 17Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2009 Financial Results 18Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 2Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 3Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 4Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility 5
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... (NAPW) honors Kathy Everette-Gaines as a 2015-2016 inductee ... She is recognized with this prestigious distinction for ... networking organization exclusively for professional women, boasting more ... Chapters. , “I’m pleased to welcome Kathy into ...
(Date:6/1/2015)... June 02, 2015 Dr. ... SC-based Piedmont Physical Medicine & Rehabilitation, P.A., has ... benefits of stem cell therapy for knees, and ... cases preferred alternative to arthroscopy or knee joint ... practitioner of Neuromusculoskeletal, Vascular and Regenerative Medicine, writes ...
(Date:6/1/2015)... New York, New York (PRWEB) June 01, 2015 ... lawsuits ( http://www.testosteronelawsuithub.com/ ) has amended the Case ... AbbVie, Inc.’s AndroGel testosterone gel. The Amended Order ... District of Illinois on May 29, 2015, directs the ... the Court by August 10, 2015 that outlines parameters ...
(Date:6/1/2015)... 01, 2015 The Delta Dental Foundation ... and organizations in Michigan, Ohio and Indiana for its ... Sept. 30, 2015 has been set. , Across the ... to organizations that specifically focus on children’s oral health ... oral health in adults. Each grant request will be ...
(Date:6/1/2015)... On May 14, 2015, the AFC/Doctors ... Cherry Creek Chamber of Commerce for the grand opening ... typically do not offer primary care services by appointment; ... Urgent Care staff to schedule family care procedures, such ... 7:30 p.m. the center hosted presidents, CEOs, and managers ...
Breaking Medicine News(10 mins):Health News:The National Association of Professional Women Inducts Kathy Everette-Gaines, Community Relations Coordinator, Into its VIP Professional Woman of the Year Circle 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 2Health News:New Article by Dr. Robert G. Schwartz of Piedmont Physical Medicine & Rehabilitation Looks at Benefits of Stem Cell Therapy for Knees 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 2Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 3Health News:Testosterone Lawsuit News: Federal Court Amends Order Governing AndroGel Bellwether Trial Selection 4Health News:Brighter Futures Community Grants Program Seeks to Help Fund Local Oral Health Programs 2Health News:Grand Opening For AFC/Doctors Express Cherry Creek Primary Care Clinic 2
... 27 MediSend International has joined The Clinton ... to Action , a unique feature of CGI ... measurable results. Through its Afghanistan Health and Human ... training, comprehensive repair and maintenance kits, technical support ...
... fibrillation, other arrhythmias , MONDAY, Oct. 26 (HealthDay ... hard evidence that the characteristic snorting and gasping ... abnormalities. , Previous studies have suggested an association ... had not established a cause-and-effect relationship, said study ...
... with pleasure that the Spain-United States Chamber of Commerce ... which is slated to increase attendance in 2009, will be held ... Nov. 6th. The gala recognizes Spain-native, U.S.-based companies and ... This year, The Chamber will honor IBT GROUP ...
... of severe physical, psychosocial suffering, researchers say , MONDAY, ... World War II, those who were potentially exposed to ... due to physical and mental stress, an Israeli study ... rates in more than 300,000 Israeli Jews who were ...
... that a sometimes deadly stomach bug, Clostridium difficile ... Clostridium difficile is a serious bacteria that ... of the colon. These findings were presented today at ... in San Diego. Clostridium difficile , often ...
... BOSTON, Oct. 26 Uno Chicago Grill®, America,s Healthiest Chain ... limited-time-only fall menu. , This exciting fall menu ... cranberries are a well-known and popular accent to many dishes, ... once the territory of a select few health food aficionados. ...
Cached Medicine News:Health News:MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative 2Health News:MediSend International Joins the Clinton Global Initiative With the Afghanistan Health and Human Resource Initiative 3Health News:Sleep Apnea Episodes May Trigger Irregular Heartbeat 2Health News:Spain-United States Chamber of Commerce Announces 30th Annual Gala Honoring IBT Group at The Biltmore Hotel - November 6 2Health News:Exposure to Holocaust May Have Raised Cancer Risks 2Health News:Deadly stomach infection rising in community settings, Mayo Clinic study finds 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 2Health News:Go, Go, Goji! UNO(R) Fall Menu Is 'Berry' Delicious 3
This EIA microplate opens new perspectives in the direct detection of Chlamydia. The choice of microplate immunoenzymatic technology and the use of a monoclonal antibody result in a combination of c...
... of rubella IgG antibody in women prior ... from possible rubella viral infection during pregnancy. ... greatly reduced the incidence of rubella epidemics, ... monitoring of immune status, especially for women ...
... Demonstration of rubella IgG antibody in women ... protection from possible rubella viral infection during ... has greatly reduced the incidence of rubella ... accurate monitoring of immune status, especially for ...
... Every Bard BrachyStar® Needle is designed ... an efficient and clinically effective brachytherapy procedure. ... featuring ultra-sharp tips and polished surfaces for ... of needle configurations and sizes assures an ...
Medicine Products: